- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT05268289
활동성 루푸스 신염 Class III-IV, +/- V 환자에서 LNP023의 효능 및 안전성 연구
활동성 루푸스 환자에서 경구용 코르티코스테로이드를 사용하거나 사용하지 않는 표준 치료와 LNP023의 효능, 안전성 및 내약성을 평가하기 위한 적응형, 무작위, 이중맹검, 용량 탐색, 병렬 그룹, 위약 대조, 다기관 2상 시험 신장염 등급 III-IV, +/- V
The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment.
연구 개요
상태
정황
상세 설명
The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment.
연구 유형
등록 (실제)
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
-
Mainz, 독일, 55131
- Novartis Investigative Site
-
-
Lower Saxony
-
Braunschweig, Lower Saxony, 독일, 38126
- Novartis Investigative Site
-
-
-
-
-
Selangor Darul Ehsan, 말레이시아, 68100
- Novartis Investigative Site
-
-
Pahang
-
Kuantan, Pahang, 말레이시아, 25100
- Novartis Investigative Site
-
-
Perak
-
Taiping, Perak, 말레이시아, 34000
- Novartis Investigative Site
-
-
-
-
-
Aguascalientes, 멕시코, 20230
- Novartis Investigative Site
-
Veracruz, 멕시코, 91900
- Novartis Investigative Site
-
-
Tamaulipas
-
Tampico, Tamaulipas, 멕시코, 89440
- Novartis Investigative Site
-
-
Yucatán
-
Mérida, Yucatán, 멕시코, 97070
- Novartis Investigative Site
-
-
-
-
California
-
San Bernardino, California, 미국, 92408
- Loma Linda University
-
-
Illinois
-
Hinsdale, Illinois, 미국, 60521
- Nep Assoc of Northern Illinois
-
-
-
-
-
Salvador, 브라질, 40323-010
- Novartis Investigative Site
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, 브라질, 40150-150
- Novartis Investigative Site
-
-
Minas Gerais
-
Belo Horizonte, Minas Gerais, 브라질, 30150-221
- Novartis Investigative Site
-
-
São Paulo
-
São Paulo, São Paulo, 브라질, 05403-000
- Novartis Investigative Site
-
São Paulo, São Paulo, 브라질, 04038-002
- Novartis Investigative Site
-
-
-
-
Singapore
-
Singapore, Singapore, 싱가포르, 308433
- Novartis Investigative Site
-
-
-
-
-
Santa Fe, 아르헨티나, S3000EPV
- Novartis Investigative Site
-
-
-
-
-
Cambridge, 영국, CB2 0QQ
- Novartis Investigative Site
-
-
-
-
Kerala
-
Kozhikode, Kerala, 인도, 673008
- Novartis Investigative Site
-
-
National Capital Territory of Delhi
-
New Delhi, National Capital Territory of Delhi, 인도, 110029
- Novartis Investigative Site
-
-
Telangana
-
Hyderabad, Telangana, 인도, 500082
- Novartis Investigative Site
-
-
-
-
-
Shenzhen, 중국, 518036
- Novartis Investigative Site
-
-
Guangxi
-
Nanning, Guangxi, 중국, 530022
- Novartis Investigative Site
-
-
Ningxia
-
Yinchuan, Ningxia, 중국, 750004
- Novartis Investigative Site
-
-
-
-
-
Montería, 콜롬비아, 230004
- Novartis Investigative Site
-
-
Atlántico
-
Barranquilla, Atlántico, 콜롬비아, 080020
- Novartis Investigative Site
-
-
Cundinamarca
-
Bogota, Cundinamarca, 콜롬비아, 111411
- Novartis Investigative Site
-
-
Santander Department
-
Bucaramanga, Santander Department, 콜롬비아, 680003
- Novartis Investigative Site
-
-
-
-
Melikgazi
-
Kayseri, Melikgazi, 터키 (Türkiye), 38039
- Novartis Investigative Site
-
-
Yenimahalle
-
Ankara, Yenimahalle, 터키 (Türkiye), 06500
- Novartis Investigative Site
-
-
Yenisehir
-
Mersin, Yenisehir, 터키 (Türkiye), 33110
- Novartis Investigative Site
-
-
-
-
-
Coimbra, 포르투갈, 3004-561
- Novartis Investigative Site
-
-
-
-
-
Marseille, 프랑스, 13005
- Novartis Investigative Site
-
Nantes, 프랑스, 44093
- Novartis Investigative Site
-
-
-
-
-
Quezon, 필리핀 제도, 1102
- Novartis Investigative Site
-
-
National Capital Region
-
Makati City, National Capital Region, 필리핀 제도, 1218
- Novartis Investigative Site
-
-
-
-
Hong Kong
-
Hong Kong, Hong Kong, 홍콩, 999077
- Novartis Investigative Site
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
Unequivocally positive ANA test result and/or a positive anti dsDNA at screening Active biopsy-proven lupus nephritis within 3 months of screening demonstrating Class III or IV lupus nephritis with or without co-existing features of Class V lupus nephritis.
Documentation of active renal disease at the time of screening necessitating the commencement of therapy with corticosteroids in combination with MMF/MPS.
eGFR ≥ 30 ml/min/1.73 m2 Vaccination against Neisseria meningitidis and Streptococcus pneumoniae infections Vaccination against Haemophilus influenzae infection Supportive care including stable dose regimen of anti-malarials (e.g. hydroxychloroquine) unless contraindicated, ACEi or ARB at either locally approved maximal daily dose or the maximally tolerated dose (per investigators' judgement) at screening, as per the local clinical practice. Doses should remain stable throughout the study.
First presentation or flare of lupus nephritis.
Exclusion Criteria:
Induction treatment with cyclophosphamide within 3 months of planned treatment for this study; treatment with calcineurin inhibitors within the previous 3 months prior to randomization.
Presence of rapidly progressive glomerulonephritis (RPGN) as defined by 50% decline in eGFR within 3 months prior to screening.
Renal biopsy presenting with interstitial fibrosis/tubular atrophy (IF/TA) or glomerulosclerosis of more than 50%, or which in the opinion of the investigator is such that it precludes likely response to immunosuppressive therapy.
Participants being treated with systemic corticosteroids (>5 mg/day prednisone or equivalent) for indications other than SLE or LN e.g. acute asthma, inflammatory bowel disease.
Participants being treated with systemic corticosteroids for SLE or LN will be excluded if they have taken more than an average of 15 mg/day prednisone (or equivalent) in the previous 4 weeks and more than an average of 30 mg/day in the previous 1 week Receipt of more than a total dose of 1000 mg equivalent i.v. pulse methylprednisolone (cumulative dose) within 2 weeks prior to enrollment (and at enrollment)
Other protocol-defined inclusion/exclusion criteria may apply
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 순차적 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
활성 비교기: Iptacopan + standard of care (part 1)
Iptacopan + standard of care |
Taken for 52 Weeks
다른 이름들:
|
|
위약 비교기: Placebo matching iptacopan + standard of care (part 1)
Placebo matching iptacopan standard of care |
Taken for 52 Weeks |
|
활성 비교기: Iptacopan + standard of care (part 2)
Iptacopan + standard of care |
Taken for 52 Weeks
다른 이름들:
|
|
활성 비교기: Iptacopan + placebo (part 2)
Iptacopan + placebo standard of care |
Taken for 52 Weeks
다른 이름들:
|
|
활성 비교기: Placebo matching iptacopan + standard of care (part 2)
Placebo matching iptacopan + standard of care |
Taken for 52 Weeks |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Part 1 and 2: Proportion of patients achieving Complete Renal Response (CRR) at week 24 in the absence of renal flares
기간: Baseline and week 24
|
Part 1: To evaluate the proportion of patients achieving complete renal response with iptacopan treatment "A" plus standard of care, compared to treatment alone Part 2: To evaluate the proportion of patients achieving complete renal response with Iptacopan treatment "B" plus standard of care, compared to treatment "D" alone Part 2: To evaluate the proportion of patients achieving complete renal response with Iptacopan treatment "C" plus standard of care, compared to treatment "D" alone Complete Renal Response is defined as meeting the following criteria: estimated glomerular filtration rate (eGFR) ≥ 90 mL/min/1.73 m2 or no less than 85% of baseline value, and 24h urine protein-to-creatinine ratio (UPCR) ≤ 0.5 g/g. |
Baseline and week 24
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Parts 1 and 2: Proportion of patients achieving CRR or PRR in the absence of renal flares
기간: Baseline, week 24, week 52
|
Proportion of patients achieving complete renal response or partial renal response |
Baseline, week 24, week 52
|
|
Proportion of patients achieving ≥25% UPCR reduction in the absence of renal flares compared to baseline at week 24
기간: Baseline, week 24 week 52
|
Frequency of renal flares between weeks 24 and 52 |
Baseline, week 24 week 52
|
|
Log-transformed ratio to baseline of 24h UPCR at week 24
기간: Baseline week 24
|
Dose exposure response for reduction in proteinurea. (each 24h urine protein-to-creatinine ratio value will based on two 24 urine collections sampled within 10 days before the respective study visit) |
Baseline week 24
|
|
Change from baseline FACIT-Fatigue Score
기간: Weeks 24 and 52
|
Measure fatigue in patients |
Weeks 24 and 52
|
|
Change from baseline in SLEDAI-2K score at weeks 24 and 52
기간: Weeks 24 and 52
|
Measure disease activity in SLE |
Weeks 24 and 52
|
|
Change from baseline in BILAG-2004 score at weeks 24 and 52
기간: Weeks 24 and 52
|
Measure disease activity |
Weeks 24 and 52
|
|
Time-to-Complete Renal Response (CRR) based on first morning void(FMV) urine samples
기간: Week 24 and Week 52
|
Measurement of time to complete renal response based on urine samples |
Week 24 and Week 52
|
공동 작업자 및 조사자
수사관
- 연구 책임자: Novartis Pharmaceuticals, Novartis Pharmaceuticals
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- CLNP023K12201
- 2021-002046-33 (EudraCT 번호)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .